Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

<i>Background and Objectives</i>: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficien...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shinsuke Suzuki, Satoshi Toyoma, Yohei Kawasaki, Koh Koizumi, Nobuko Iikawa, Kazuhiro Shiina, Tentaro Endo, Tomoe Abe, Teppei Kouga, Takechiyo Yamada
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-10-01
coleção:	Medicina
Assuntos:	head and neck squamous cell carcinoma cetuximab paclitaxel immune checkpoint inhibitor chemotherapy
Acesso em linha:	https://www.mdpi.com/1648-9144/57/11/1151
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!